Prab: CSV import

2025-03-18T03:02:02Z

CSV import

← Older revision		Revision as of 03:02, 18 March 2025
Line 37:		Line 37:
	{{pharmacology-stub}}		{{pharmacology-stub}}
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-11T04:17:53Z

CSV import

← Older revision		Revision as of 04:17, 11 February 2025
Line 36:		Line 36:

	{{pharmacology-stub}}		{{pharmacology-stub}}
			{{No image}}

Prab: CSV import

2024-03-08T19:53:34Z

CSV import

New page

'''Target-mediated drug disposition''' (TMDD) is a term used in [[pharmacokinetics]] to describe the phenomenon where the [[pharmacokinetics]] of a drug are significantly affected by its own [[pharmacodynamics]]. This typically occurs when a drug has a high affinity for a specific [[target]] such as a [[receptor]], [[enzyme]], or [[transporter]], and the drug-target interaction significantly influences the drug's distribution and elimination.

== Overview ==

TMDD is often observed with [[biologic drugs]], including [[monoclonal antibodies]], [[recombinant proteins]], and [[gene therapies]]. These drugs often have high affinities for their targets, and the targets can be present in limited quantities. As a result, the drug-target interaction can significantly influence the drug's pharmacokinetics.

== Mechanism ==

The mechanism of TMDD involves the binding of the drug to its target. This binding can lead to the internalization and degradation of the drug-target complex, effectively removing the drug from circulation. This can result in nonlinear pharmacokinetics, where the drug's clearance rate changes with its concentration.

In some cases, the target can be upregulated in response to drug binding, leading to an increase in the drug's clearance rate. This is known as target-mediated drug induction.

== Mathematical modeling ==

Mathematical models have been developed to describe and predict the pharmacokinetics of drugs exhibiting TMDD. These models typically involve differential equations that describe the rates of drug absorption, distribution, metabolism, and excretion, as well as the rates of target binding and internalization.

== Clinical implications ==

Understanding TMDD is important for the development and dosing of new drugs. If a drug exhibits TMDD, its dose-response relationship may be nonlinear, and its optimal dose may depend on the patient's target levels. Additionally, TMDD can lead to variability in drug response between patients, which can complicate drug development and dosing strategies.

== See also ==

* [[Pharmacokinetics]]
* [[Pharmacodynamics]]
* [[Biologic drugs]]
* [[Monoclonal antibodies]]
* [[Recombinant proteins]]
* [[Gene therapies]]

[[Category:Pharmacokinetics]]
[[Category:Pharmacodynamics]]
[[Category:Biologic drugs]]
[[Category:Monoclonal antibodies]]
[[Category:Recombinant proteins]]
[[Category:Gene therapies]]

{{pharmacology-stub}}

Target-mediated drug disposition - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import